Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside

Background: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2/neu) antibody, is considered a standard treatment in addition to chemotherapy in the adjuvant setting for HER2/neu-positive breast cancer, yet its impact on fertility and ovarian reserve remains obscure. We aime...

Full description

Bibliographic Details
Main Authors: Mattan Levi, Tal Goshen-Lago, Rinat Yerushalmi, Tal Granot, Salomon M. Stemmer, Ruth Shalgi, Irit Ben-Aharon
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Biomedicines
Subjects:
ovarian toxicity
chemotherapy
anti-HER2/neu
trastuzumab
Online Access:https://www.mdpi.com/2227-9059/8/12/577

Internet

https://www.mdpi.com/2227-9059/8/12/577

Similar Items